Results 11 to 20 of about 48,247 (244)
Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study [PDF]
Revista Brasileira de OftalmologiaObjective: To report the frequency of ocular manifestations in patients undergoing direct-acting antiviral therapy and assess treatment safety based on outcomes; to identify demographic variables associated with hepatitis C virus infection; evaluate ...
Guilherme Thomé de Carvalho +7 more
doaj +1 more source
Direct-acting antivirals for chronic hepatitis C [PDF]
Cochrane Database of Systematic Reviews, 2016 Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C. +15 more
openaire +8 more sources
Viruses, 2022 Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain uncertain.
Shou-Wu Lee +4 more
doaj +1 more source
New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]
Hepatology, 2013 Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Aghemo, Alessio, De Francesco, Raffaele
openaire +2 more sources
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]
Clinical and Molecular Hepatology, 2015 Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho +5 more
doaj +1 more source
BMC Infectious Diseases, 2019 Background Almost 1% of Canadians are hepatitis C (HCV)-infected. The liver-specific complications of HCV are established but the extra-hepatic comorbidity, multimorbidity, and its relationship with HCV treatment, is less well known.
Curtis L. Cooper +6 more
doaj +1 more source
HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus
BMC Endocrine Disorders, 2022 Background The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM. Methods A retrospective cohort study was conducted using
Marina Angel +3 more
doaj +1 more source
PLoS ONE, 2019 BackgroundData on initiation and utilization of direct-acting antiviral therapies for hepatitis C virus infection in the United States are limited. This study evaluated treatment initiation, time to treatment, and real-world effectiveness of direct ...
Paul Y Kwo +5 more
doaj +1 more source
Journal of Mind and Medical Sciences, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Olga H. Orasan +12 more
doaj +1 more source
Update on hepatitis C: Direct-acting antivirals
World Journal of Hepatology, 2015 Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert +2 more
openaire +2 more sources